Relation of Efficacy of Combined Use of Ibandronic Acid and Alfacalcidol with Bone Tissue Remodeling in Women with Postmenopausal Form of Osteoporosis

Abstract

Study of 51 female patients showed high efficacy of alfacalcidol (Alfa D3 - Teva) and ibandronic acid (Bonviva) combination for the treatment of postmenopausal form of systemic osteoporosis. Dependence of mineral bone density (MBD) on the primary intensity of bone tissue remodeling was observed. Assumption on the necessity of bone metabolism markers assessment at ibandronate use was confirmed. The fact that use of active form of vitamin D 3 eliminates such side effects of bisphosphonates as secondary hyperparathyroidism and hypocalcemia has been proved.

References

  1. Балаболкин М.И. Эндокринология. - М., 1998.
  2. Armamento-Villareal R., Napoli N., Diemer K., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series //Calcif. Tissue Int. - 2009. - Vol. 85, N 1. - P. 37-44.
  3. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy //J. Bone Jt Surg. Am. - 2009. - Vol. 91, N 11. - P. 2556-2561.
  4. Delmas P.D., Adami S., Strugala C., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study //Arthritis Rheum. - 2006. - Vol. 54. - P. 1838 - 1846.
  5. Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat //Osteoporos Int. - 1996. - Vol. 6. - P. 166-170.
  6. Gasser A.B., Morgan D.B., Fleisch H.A. et al. The influence of two diphosphonates on calcium metabolism in the rat //Clin. Sci. - 1972. - Vol. 43. - P. 31-45.
  7. Ing-Lorenzini K., Desmeules J., Plachta O., et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospita» //Drug Saf. - 2009. - Vol.32, N9. - P. 775-785.
  8. Iwamoto J., Takeda T., Ichimura S., et al. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis //J. Orthop. Sci. - 2003. - Vol. 8. - P. 532-537.
  9. Kataxaki E., Koulouris G., Marketos G. et al. Combined treatment of alendronate plus alphacalcidol (One-Alpha® LEO Pharma©) on bone mass in postmenopausal osteoporosis //Calcif. Tissue Int. - 2004. - Vol. 74. - P. 87-88.
  10. Masarachia P., Weinreb M., Balena R., Rodan G. A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones //Bone. - 1996. - Vol. 19. - P. 281-290.
  11. Masud T., Mulcahy B., Thompson A.V. et al. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck one mineral density in postmenopausal osteoporotic women //Ann. Rheum. Dis. - 1998. - Vol. 57. - P. 346-349.
  12. Orimo H., Nakamura T., Fukunaga M., et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02 //Curr. Med. Res. Opin. - 2011. - Vol. 26, N 7. - P. 1273-1284.
  13. Prescribing information. Zometa (zoledronic acid). Available at http://www.pharma.us.novartis.com.
  14. Rogers M. J. New insights into the molecular mechanism of action of bisphosphonates //Curr. Pharm. Res. - 2003. - Vol. 11. - P. 196-204.
  15. Sahni M., Guenther H.L., Fleisch H. et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts //J. Clin. Invest. - 1993. - Vol. 91 - P. 2004-2011.
  16. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol //Calcif. Tissue. Int. - 1999. - Vol. 65. - P. 317-327.
  17. Shiota E., Tsuchiya K., Yamaoka ., K, Kawano O. Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alfacalcidol in postmenopausal osteoporosis //J. Orthop. Sci. - 2001. - Vol. 6. - P. 133-136.
  18. Shiraishi A., Takeda S., Masaki T. et al., Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct action from estrogen //J. Bone Miner. Res. - 2000. - Vol. 15. - P. 770-779.
  19. Sorscher S. Electrolyte abnormalities with zoledronic acid therapy //Cancer J. - 2002. - Vol. 8, N 4. - P. 348.
  20. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility //J. Clin. Endocrinol. Metab. - 2008. - Vol. 93, N 8. - P. 2948-2952.

Statistics

Views

Abstract: 114

Cited-by

CrossRef: 1

  1. Rodionova SS, Lekishvili MV, Sklyanchuk ED, Torgashin AN, Ryabov AY, Yurasova YB. Prospects for Local Application of Antiresorptive Drugs in Skeleton Bone Injuries and Diseases. Vestnik travmatologii i ortopedii imeni N.N. Priorova. 2014;(4):83. doi: 10.32414/0869-8678-2014-4-83-89

Dimensions

Article Metrics

Metrics Loading ...

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies